摘要
目的探讨在宫颈癌和卵巢癌患者化疗中应用聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)对中性粒细胞缺乏的预防价值。方法选取2018年1月至2019年8月商丘市第一人民医院所收治宫颈癌、卵巢癌行化疗治疗患者75例,其中38例(对照组)患者在化疗期间取重组人粒细胞刺激因子(rh G-CSF) 5 mg/kg皮下注射,37例(观察组)患者在化疗期间取PEG-rhG-CSF 100 mg/kg皮下注射,对两组患者化疗期间外周血象进行检测,对其中性粒细胞绝对计数进行计算,统计患者的粒细胞缺乏发生率、药物相关不良反应发生率。结果两组患者在化疗开始后第3天时中性粒细胞绝对计数出现一过性下降,在5~7 d达到相对最低值,在7~14 d逐渐回升,在化疗第14天时两组患者中性粒细胞绝对计数均回复到化疗开始前水平;两组患者在化疗第1、3、5、7、14天时中性粒细胞绝对计数组间比较差异未见统计学意义(P>0. 05);观察组患者Ⅲ度粒细胞缺乏症发生率为10. 81%(4/37),与对照组患者(13. 16%,5/38)比较差异未见统计学意义(P>0. 05);本研究中两组患者化疗期间骨骼肌肉疼痛、皮疹、恶心/呕吐、低热/乏力等不良反应发生率比较差异未见统计学意义(P>0. 05)。结论 PEG-rhG-CSF可有效降低宫颈癌、卵巢癌患者化疗期间粒细胞缺乏/减少的发生风险,具有同rh G-CSF相当的药物效果,但其操作更为简便,仅需一次注射即可维持有效血药浓度,对于保证化疗的顺利进行具有十分积极的作用。
Objective To investigate the preventive value of PEG-rhG-CSF on neutrophil deficiency in patients with cervical and ovarian cancer treated with PEG-rhG-CSF. Methods From January 2018 to August 2019,75 patients with cervical cancer and ovarian cancer who were treated with chemotherapy in the First People’s Hospital of Shangqiu were selected,of which 38 patients( control group) received recombinant human granulocyte stimulating factor( rhG-CSF) 5 mg/kg subcutaneous injection,37 patients( observation group) took PEG-rhG-CSF 100 mg/kg subcutaneous injection during chemotherapy. The peripheral blood images during chemotherapy were detected,the absolute neutrophil count was calculated. The incidence of agranulocytosis and drug-related adverse reactions in patients were counted. Results The absolute neutrophil counts of the two groups decreased transiently on the 3 rd day after the start of chemotherapy,reached a relatively low value on the 5 th to the 7 th day,and gradually recovered on the 7 th to the 14 th day. The two groups were neutral on the 14 th day of the chemotherapy.The absolute counts of granulocytes returned to the levels before chemotherapy started;there was no significant difference in the absolute neutrophil counts between the two groups at the 1 st,3 rd,5 th,7 th,and 14 th days of chemotherapy( P > 0. 05). The incidence of grade Ⅲ agranulocytosis in the observation group was 10. 81%( 4/37),which was not significantly different from that in the control group( 13. 16%,5/38)( P >0. 05). There was no significant difference in the incidence of skeletal muscle pain,rash,nausea/vomiting,low fever/weakness or other adverse reactions during chemotherapy between the two groups of patients( P > 0. 05). Conclusions PEG-rhG-CSF can effectively reduce the risk of agranulocytosis/decrease in patients with cervical cancer and ovarian cancer during chemotherapy.Maintaining effective blood drug concentration has very positive effect on ensuring the smooth progress of chemotherapy.
作者
郭银谋
Guo Yinmou(Department of Oncology,the First People’s Hospital of Shangqiu,Shangqiu 476100,China)
出处
《临床医学》
CAS
2020年第7期92-95,共4页
Clinical Medicine
关键词
宫颈癌
卵巢癌
化疗并发症
粒细胞缺乏
聚乙二醇化重组人粒细胞刺激因子
重组人粒细胞刺激因子
Cervical cancer
Ovarian cancer
Chemotherapy complications
Agranulocytosis
PEGylated recombinant human granulocyte stimulating factor
Recombinant human granulocyte stimulating factor
